<DOC>
	<DOC>NCT02854488</DOC>
	<brief_summary>The study is a global safety surveillance study of pregnancy outcomes in women who were exposed to ipilimumab during pregnancy and pediatric outcomes up to 5 years of age</brief_summary>
	<brief_title>Yervoy Pregnancy Surveillance Study</brief_title>
	<detailed_description />
	<criteria>Documented exposure to Yervoy while pregnant or within 90 days of discontinuing treatment Women whose ipilimumab exposure is outside the window of pregnancy exposure Pregnancies for which there is only paternal exposure to Yervoy Other protocol defined inclusion/exclusion criteria could apply</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>